Satraplatin for second-line treatment of hormone-refractory prostate cancer - horizon scanning review
NHSC
Record ID 32004000879
English
Authors' objectives:
To summarise the currently available evidence on satraplatin for second-line treatment of hormone-refractory prostate cancer.
Authors' recommendations:
Satraplatin, an orally-active platinum compound, is in phase III clinical trials as a second-line treatment for men with hormone-refractory prostate cancer (HRPC) who no longer respond or are refractory to first-line chemotherapy. Results of a preliminary phase III trial of satraplatin in combination with prednisone versus prednisone alone as first-line chemotherapy in HRPC has been reported in abstract form. Treatment with satraplatin significantly lengthened time to progression (5.2 months versus 2.5 months). At 6 months, 41% of patients treated in the satraplatin arm were progression free versus 22% of patients in the control arm.
Authors' methods:
Overview
Details
Project Status:
Completed
Year Published:
2004
URL for published report:
http://www.psy-flow.com/sites/psy-flow/files/docs/flow.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Antineoplastic Agents
- Organoplatinum Compounds
- Prostatic Neoplasms
Contact
Organisation Name:
NIHR Horizon Scanning Centre
Contact Address:
The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
c.packer@bham.ac.uk
Contact Email:
c.packer@bham.ac.uk
Copyright:
National Horizon Scanning Centre (NHSC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.